Perspective Therapeutics, INC. (CATX) — 10-Q Filings

10-Q Filings (5)

• CATX Q3 Loss Widens on Soaring R&D Costs, Cash Drains — Nov 10, 2025 Risk: high
  Perspective Therapeutics, Inc. (CATX) reported a significant increase in net loss for the nine months ended September 30, 2025, reaching $65.631 million, compar
• CATX R&D Surge Drives Q2 Loss to $21.5M Amid Cash Burn — Aug 13, 2025 Risk: high
  Perspective Therapeutics, Inc. (CATX) reported a significant increase in net loss for the three and six months ended June 30, 2025, primarily driven by a substa
• Perspective Therapeutics Files 10-Q, Reveals Past Names — May 12, 2025 Risk: low
  Perspective Therapeutics, Inc. filed its 10-Q for the period ending March 31, 2025. The filing indicates the company's fiscal year ends on December 31st. Previo
• Perspective Therapeutics Files Q3 10-Q, Cites Key Agreements — Nov 12, 2024 Risk: medium
  Perspective Therapeutics, Inc. filed its 10-Q for the period ending September 30, 2024. The company, formerly known as Isoray, Inc., is in the surgical and medi
• Perspective Therapeutics Files Q2 2024 10-Q — Aug 13, 2024 Risk: medium
  Perspective Therapeutics, Inc. (formerly Isoray, Inc.) filed its 10-Q for the period ending June 30, 2024. The filing details financial performance and operatio

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX